Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Commvault Systems Inc (CVLT) vs Mesoblast Limited (MESO) Price & Performance

Commvault Systems IncTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Commvault Systems Inc vs Mesoblast Limited — how do they compare? Commvault Systems Inc trades at $139.62 (market cap $5.78B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Commvault Systems Inc is far larger — about 2.7× Mesoblast Limited's market cap. Which is the better fit depends on your goals.

CVLTMESO
Market Cap
$5.78B$2.16B
Sector
TechnologyTechnology
52-Week High
$195.41$20.96
52-Week Low
$75.18$12.88
Enterprise Value
$5.77B$2.17B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Commvault Systems Inc

Commvault Systems (CVLT) trades at $135.27, up 1.43% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust profitability with an 81.09% gross margin and 32.77% ROE, though valuation multiples like a P/E of 89.38 are elevated. Recent news highlights growth in SaaS revenue and new security integrations, such as the Threat Scan partnership with Google, driving positive analyst sentiment.

The outlook remains positive with a consensus price target of $172.40, implying 27% upside, supported by subscription growth and cash flow improvements. Risks include high valuation sensitivity, competitive pressures in data security, and fiduciary duty investigations noted in recent legal alerts, which could impact investor confidence near-term.

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

Returns comparison

Trailing returns across standard periods

About Commvault Systems Inc

Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.

Read more on CVLT

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO